Huakang Biomedical Delays Dispatch of Composite Document for Anselme Buyout
Anselme Limited has postponed the dispatch of the composite document regarding its plan to acquire all shares of Huakang Biomedical Holdings. This includes the cancellation of all outstanding share options not already owned or agreed to be acquired by Anselme and its concert parties. Further details will be provided later, as stated in a joint announcement from both companies.
Anselme Limited has delayed the dispatch of the composite document related to its previously announced intention to acquire all the issued shares of Huakang Biomedical Holdings Company Limited, as well as to cancel all outstanding share options not already owned or agreed to be acquired by Anselme Limited and its concert parties. Further details will be provided in due course, according to a joint statement from the companies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Huakang Biomedical Holdings Co. Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
